Pharsight

Epsolay is owned by Galderma Labs Lp.

Epsolay contains Benzoyl Peroxide.

Epsolay has a total of 6 drug patents out of which 0 drug patents have expired.

Epsolay was authorised for market use on 22 April, 2022.

Epsolay is available in cream;topical dosage forms.

Epsolay can be used as topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older, topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older.

The generics of Epsolay are possible to be released after 18 August, 2040.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868103	GALDERMA LABS LP	Metal oxide coating of water insoluble ingredients	Aug, 2028 (5 years from now)
US9687465	GALDERMA LABS LP	Compositions for the treatment of rosacea	Nov, 2032 (9 years from now)
US10945987	GALDERMA LABS LP	Method for providing early onset of action in the treatment of rosacea	Feb, 2040 (16 years from now)
US10933046	GALDERMA LABS LP	Method for treatment of rosacea in patients aged 65 years and older	Feb, 2040 (16 years from now)
US11541026	GALDERMA LABS LP	Method for treatment of rosacea	Feb, 2040 (16 years from now)
US11426378	GALDERMA LABS LP	Method for long-term treatment of rosacea	Aug, 2040 (17 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older; Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older

Dosage: CREAM;TOPICAL